NEW YORK – Agendia said today that it has partnered with PathoNext to offer its MammaPrint BluePrint Breast Cancer Recurrence and Molecular Subtyping tests in Germany.
As part of the agreement, PathoNext will run the tests in its own labs using next-generation sequencing (NGS) and partner with HiSS, Agendia's distributor in Germany, to offer the tests to German patients.
Agendia's MammaPrint panel analyzes 70 genes most associated with breast cancer recurrence to provide a binary risk of cancer recurrence results. The firm's BluePrint gene expression assay analyzes 80 genes that classify a patient's breast cancer into functional molecular subtypes.
The Irvine, California-based firm has also developed its integrated NGS MammaPrint BluePrint Breast Cancer Recurrence and Molecular Subtyping Kit — a CE-marked RNA-sequencing based kit version of its existing microarray-based tests — to address testing needs outside its central lab.
"We are confident that PathoNext will deliver the same high-quality performance as they do with their other tests," Mark Straley, CEO of Agendia, said in a statement. "Together, we will bring Agendia's high-quality testing to the nearly 25,000 women annually diagnosed with breast cancer in Germany."
Financial details of the agreement were not disclosed.
"With the growing cancer burden globally, and increasing incidence of diagnoses, Agendia's MammaPrint and BluePrint are a perfect complement to our molecular pathology division," Jörg Gabert, CEO of PathoNext, said in a statement. "We are pleased to help breast cancer patients, both in obtaining an appropriate diagnosis, and in the choice of a fully personalized treatment."